Altamira Therapeutics Ltd. (CYTO)

NASDAQ: CYTO · IEX Real-Time Price · USD
2.430
+0.550 (29.26%)
At close: Mar 1, 2024, 4:00 PM
2.348
-0.082 (-3.37%)
After-hours: Mar 1, 2024, 7:59 PM EST
29.26%
Market Cap 3.83M
Revenue (ttm) -902,126
Net Income (ttm) -27.38M
Shares Out 1.58M
EPS (ttm) -474.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 729,748
Open 1.880
Previous Close 1.880
Day's Range 1.880 - 2.460
52-Week Range 1.610 - 101.600
Beta 2.49
Analysts n/a
Price Target n/a
Earnings Date Sep 12, 2023

About CYTO

Altamira Therapeutics Ltd., a clinical-and commercial-stage biopharmaceutical company, engages in the development of therapeutics that address various unmet medical needs in Switzerland, the United States, Europe, and Australia. The company develops OligoPhore/SemaPhore, a platform for delivery of oligonucleotides, such as small interfering ribonucleic acid or messenger RNA into target cells. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also devel... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 16
Stock Exchange NASDAQ
Ticker Symbol CYTO
Full Company Profile

Financial Performance

In 2022, CYTO's revenue was 305,616, an increase of 378.41% compared to the previous year's 63,882. Losses were -26.53 million, 55.5% more than in 2021.

Financial numbers in CHF Financial Statements

News

Altamira Therapeutics' Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal

HAMILTON, BERMUDA, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Independent peer-reviewed study shows enhanced cell transduction with adeno-associated virus (AAV) vectors, commonly used in gene therapy, when int...

25 days ago - GlobeNewsWire

Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment

HAMILTON, BERMUDA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA, Jan. 24, 2024 -- Altamira Therapeutics Ltd. (Nasdaq: CYTO) ("Altamira" or the "Company"), a company providing nanoparticle-based...

5 weeks ago - GlobeNewsWire

Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit

HAMILTON, BERMUDA , Jan. 08, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit

7 weeks ago - GlobeNewsWire

Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

HAMILTON, BERMUDA, Dec. 29, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA, Dec. 29, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based...

2 months ago - GlobeNewsWire

Altamira Therapeutics to Host Investor & Business Update Call on December 11th

HAMILTON, BERMUDA , Dec. 05, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA--December 5, 2023--Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing th...

3 months ago - GlobeNewsWire

These advisers say markets are expecting unrealistic outcomes. Here are some alternatives.

Stocks are poised for an upbeat finish to the best month of gains for 2023, as the fever pitch around Fed rate cuts next year grows. It's all teeing up nicely for that Santa rally, maybe.

3 months ago - Market Watch

Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

- Partial spin-off of Bentrio® completed to increase focus on RNA delivery activities - Retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue HAMILTON, BERMUDA, Nov. 29, 2023 ...

3 months ago - GlobeNewsWire

Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business

Initiates Strategic Repositioning to Focus on Company's Core RNA Delivery Technology Altamira Therapeutics retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue Hamilton, Berm...

3 months ago - GlobeNewsWire

Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine

Hamilton, Bermuda, Nov. 10, 2023 (GLOBE NEWSWIRE) -- November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that ad...

4 months ago - GlobeNewsWire

Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis

HAMILTON, BERMUDA , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announ...

6 months ago - GlobeNewsWire

Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results

HAMILTON, BERMUDA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs, today provided a bu...

6 months ago - GlobeNewsWire

Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th

HAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important un...

6 months ago - GlobeNewsWire

Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unme...

6 months ago - GlobeNewsWire

Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia

HAMILTON, BERMUDA, July 20, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unme...

8 months ago - GlobeNewsWire

Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal

HAMILTON, BERMUDA, July 17, 2023 (GLOBE NEWSWIRE) -- -Detailed results from house dust mite trial published in Clinical and Translational Allergy -Study demonstrates statistically significant alleviat...

8 months ago - GlobeNewsWire

Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering

HAMILTON, BERMUDA / ACCESSWIRE / July 6, 2023 / Altamira Therapeutics Ltd. ("Company") (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond t...

8 months ago - Accesswire

Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration

HAMILTON, BERMUDA , July 05, 2023 (GLOBE NEWSWIRE) -- Heqet will test nanoparticles based on Altamira's OligoPhore delivery platform in the regeneration of damaged heart tissue

8 months ago - GlobeNewsWire

Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome

HAMILTON, BERMUDA / ACCESSWIRE / June 15, 2023 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet med...

9 months ago - Accesswire

Altamira Therapeutics Announces Publication of Peer-Reviewed Article on Peptide-Based RNA Delivery for Extrahepatic Targets

HAMILTON, BERMUDA / ACCESSWIRE / May 31, 2023 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced the...

9 months ago - Accesswire

Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis

Bentrio® meets primary efficacy endpoint in NASAR clinical trial in seasonal allergic rhinitis Clinically relevant and statistically significant improvement in Total Nasal Symptom Score over saline na...

10 months ago - Accesswire

Altamira Therapeutics Provides Business Update, Reports FY 2022 Financial Results

Management will host an investor conference call today, May 16th, at 8 a.m. Eastern Company is advancing OligoPhore™ / SemaPhore™ platform for extrahepatic RNA delivery and efficient endosomal release...

10 months ago - Accesswire

Altamira Therapeutics to Host Fiscal Year 2022 Financial Results and Business Update Call on May 16th 2023

HAMILTON, BERMUDA / ACCESSWIRE / May 12, 2023 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for extrahepatic targets, announ...

10 months ago - Accesswire

Altamira Therapeutics CEO & Chairman to Present at Sidoti Micro-Cap Virtual Conference May 10-11

HAMILTON, BERMUDA / ACCESSWIRE / May 1, 2023 / Altamira Therapeutics ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical ne...

10 months ago - Accesswire

Altamira Therapeutics Announces Publication of Positive Results from Phase 2 Trial with AM-125 in Acute Vestibular Syndrome in Leading Peer Reviewed Journal

Detailed results from TRAVERS trial addressing acute vestibular syndrome with AM-125 (intranasal betahistine) published in Otology & Neurotology Study demonstrates proof of concept and shows good tole...

11 months ago - Accesswire

Altamira Therapeutics Positions its Patented SemaPhore mRNA Delivery Platform as Versatile and Efficient Alternative to Lipid Nanoparticles

Altamira's peptide-based SemaPhore™ nanoparticle technology confers great stability to mRNA, is non-immunogenic and non-toxic, enabling delivery to extrahepatic targets and efficient endosomal release...

11 months ago - Accesswire